Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Mol Life Sci. 2009 Dec;66(23):3777-85. doi: 10.1007/s00018-009-0130-3. Epub 2009 Aug 26.

Group II metabotropic glutamate receptors and schizophrenia.

Author information

1
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA.

Abstract

Schizophrenia is one of the most common mental illnesses, with hereditary and environmental factors important for its etiology. All antipsychotics have in common a high affinity for monoaminergic receptors. Whereas hallucinations and delusions usually respond to typical (haloperidol-like) and atypical (clozapine-like) monoaminergic antipsychotics, their efficacy in improving negative symptoms and cognitive deficits remains inadequate. In addition, devastating side effects are a common characteristic of monoaminergic antipsychotics. Recent biochemical, preclinical and clinical findings support group II metabotropic glutamate receptors (mGluR2 and mGluR3) as a new approach to treat schizophrenia. This paper reviews the status of general knowledge of mGluR2 and mGluR3 in the psychopharmacology, genetics and neuropathology of schizophrenia.

PMID:
19707855
PMCID:
PMC2792875
DOI:
10.1007/s00018-009-0130-3
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center